ロード中...
PD-L1 inhibitors in the pipeline: Promise and progress
Checkpoint inhibitors have improved survival for patients with melanoma, non-small-cell lung cancer (NSCLC), bladder, head and neck and other cancers. Antibodies against PD-L1, including atezolizumab, avelumab and durvalumab, are also being developed and have been approved for various cancers. Compa...
保存先:
| 出版年: | Oncoimmunology |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5739559/ https://ncbi.nlm.nih.gov/pubmed/29296516 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1365209 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|